Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

  • This share is currently suspended. It was suspended at a price of 5.375

Share Price Information for Iconic Labs (ICON)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.375
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 5.375
ICON Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Name Change to Iconic Labs Plc and Results of GM

10 Jul 2019 15:59

RNS Number : 1400F
WideCells Group PLC
10 July 2019
 

10 July 2019

Iconic Labs Plc ("Iconic Labs" or the "Company")

Results of GM - Change of Name to Iconic Labs Plc

 

The Board is pleased to announce that the Company has changed its name to Iconic Labs Plc ('Iconic Labs') to reflect its new focus as a multi-divisional new media and technology business. This change takes effect following the Company's General Meeting ("GM") held today, where all resolutions were duly passed. The new ticker for the Company will be ICON and take effect on 11 July 2019.

 

Iconic Labs provides online marketing, content and technology driven products to enable companies to increase their consumer engagement and build brand presence. The team, led by John Quinlan and Liam Harrington, who were founders and key drivers behind UNILAD, the world's largest social media publisher, is making progress with regards to its new media activities, highlighted by the recently announced consulting and marketing services engagement with a UK-based financial services business, where work has commenced. 

 

The progress made has been achieved with just a soft launch; an official launch is planned, which the Company believes will benefit client acquisitions and brand awareness in the sector. The Board anticipates that the name change will be beneficial to securing new business opportunities, attracting potential complementary acquisitions as well as creating increased visibility for investors. 

 

Iconic Labs operates in a rapidly growing market driven by consumer habits shifting to digital and social from TV and print, increasing numbers of distribution platforms fighting for premium content to attract audiences, and traditional agencies struggling to adapt to client demands and new technologies. As an example, global mobile ad spend is projected to increase from US$138 billion in 2018 to US$212 billion in 2021, while Subscription Video On Demand services rose from 14% of households in 2014 to 39% in 2018. The market is fragmented, and the Board believes that, by utilising its contact base, experience of growing new media businesses and sector knowledge, it can take advantage of this fast-developing market.

 

With regards to the WideCells business, the Board continues to address legacy issues and the cash involved and will inform the market when these have been resolved. It is obviously frustrating for both the management and shareholders that there remain outstanding issues, but the Board is working to alleviate these and ensure that the new business has a firm platform that can be utilised for the benefit of all stakeholders. 

 

The Board looks forward to updating shareholders as it implements its defined growth strategy both organically and via targeted value-accretive acquisitions utilising its platform and paper.

 

Chief Executive Officer, John Quinlan, said: "I'm delighted that the name change to Iconic Labs has been effected as the name reflects the current direction of the business in the new media space. We have a proven track record in the delivery of advice, strategic planning, content provision and developing technology, primarily garnered from our time at UNILAD, which achieved revenues in excess of £10 million per annum; we are utilising this experience to build a business. There is a distinct opportunity in the new media sector and, since joining in March 2019, we have made progress establishing the offering and building out our market presence. The reception from our targeted market has been good and we are now leveraging our team's knowledge, experience and contact base to implement our strategy to create shareholder value."

 

**ENDS**

 

For further information, please visit the Company's website www.iconiclabs.co.uk or contact:

 

Shard Capital Partners LLP

Co-broker - Damon Heath, Erik Woolgar

Tel: +44 (0) 20 7186 9950

St Brides Partners Limited

PR - Melissa Hancock, Juliet Earl

Tel: +44 (0) 20 7236 1177

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCKMGMNDGMGLZM
Date   Source Headline
1st May 20187:02 amRNSAnnual Accounts and Fundraising Update
26th Mar 20187:00 amRNSLandmark deal to launch CellPlan insurance in Asia
19th Mar 20187:00 amRNSGranted Innovate UK KTP for Stem Cell Research
27th Feb 20187:00 amRNSLicence Award from the Human Tissue Authority
19th Feb 20187:00 amRNSBoard Changes and Launch of Wideacademy Platform
21st Dec 20177:00 amRNSCorporate Update
2nd Nov 20177:00 amRNSRevenue generation with White Apex agreement
12th Oct 20177:00 amRNSCellPlan expansion, e-commerce platform launch UK
11th Oct 20177:00 amRNSPartner Secured to Expand into MENA & Asia-Pacific
29th Sep 20177:00 amRNSInterim Results
25th Sep 20177:00 amRNSWideacademy Update, Presenting at Investor Event
15th Aug 20177:00 amRNSRaises £750,000 to support Company's divisions
31st Jul 20177:00 amRNSResearch Licence Granted from HTA
24th Jul 20177:00 amRNSNew product to target the dental market
21st Jul 20177:00 amRNSCellPlan launches E-Commerce Platform in the UK
12th Jul 20177:00 amRNSCorporate Charity Commitment
4th Jul 20177:00 amRNSAgreement to Roll Out CellPlan in Brazil
3rd Jul 20177:00 amRNSInvestor Evening and CFO Now Employed Full-time
27th Jun 20177:00 amRNSRevenue with launch of CellPlan
22nd Jun 20173:30 pmRNSResults of AGM
22nd Jun 20177:00 amRNSAGM Statement and Notice of Investor Evening
12th Jun 20177:00 amRNSWideAcademy Strategic Update
6th Jun 20177:00 amRNSLaunch of CellPlan set to generate maiden revenues
2nd Jun 20177:00 amRNSWideCells Named 21st in Global DISRUPT 100 List
23rd May 20177:00 amRNSAttendance at British Dental Conference
15th May 20177:00 amRNSAttendance at Brazilian Conference
4th May 20172:15 pmRNSHolding(s) in Company
2nd May 20177:40 amRNSPosting of Report and Accounts and Notice of AGM
12th Apr 20171:00 pmRNSPlacing
30th Mar 20177:00 amRNSPreliminary Results
16th Feb 20177:00 amRNSBoard Appointment
31st Jan 20177:00 amRNSDirector Purchases and Grant of Options
30th Jan 20174:40 pmRNSSecond Price Monitoring Extn
30th Jan 20174:35 pmRNSPrice Monitoring Extension
26th Jan 201710:30 amRNSGrant of Options
24th Jan 20177:00 amRNSExtends CellPlan Roll Out & New Product Launch
9th Jan 20177:00 amRNSDefinitive Agreement with BioVault for CellPlan
30th Nov 20167:00 amRNSNew Revenue Stream: Stem Cell Research, Manchester
7th Nov 20167:00 amRNSLOI with 1st Cord Blood Bank to Roll Out CellPlan
24th Oct 20167:00 amRNSCorporate Update
10th Oct 20167:00 amRNSUpdate on CellPlan
27th Sep 20167:00 amRNSPartners with University of Westminster
5th Sep 20167:00 amRNSLaunches WideCells Brasil
12th Aug 20167:00 amRNSHoldings In Company
5th Aug 20167:00 amRNSUpdate on Manchester Facility and Appointments
27th Jul 20168:00 amRNSPlacing & First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.